Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | MMP2 | P08253 | 4/20 | 0.40 |
| ▸ | MMP9 | P14780 | 4/20 | 0.40 |
| ▸ | MMP14 | P50281 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294329 | 0.92 | PTGS2 (0.44) | PTGS2MMP2MMP9MMP14POLB | |
| SCHEMBL3274519 | 0.82 | PTGS2 (0.40) | PTGS2MMP2MMP9MMP14POLB | |
| SCHEMBL16703080 | 0.80 | PTGS2 (0.49) | PTGS2MMP2MMP9MMP14POLB | |
| SCHEMBL16702992 | 0.77 | CA2 (0.50) | PTGS2MMP2MMP9MMP14POLB | |
| SCHEMBL3234259 | 0.75 | MMP2 (0.42) | PTGS2MMP2MMP9MMP14POLB | |
| SCHEMBL15994131 | 0.74 | ELANE (0.46) | MAPT | |
| SCHEMBL15994113 | 0.73 | ELANE (0.45) | KMT2AHTR2A | |
| SCHEMBL2294327 | 0.72 | PTGS2 (0.44) | PTGS2MMP2MMP9MMP14POLB | |
| SCHEMBL3262667 | 0.72 | ELANE (0.50) | PTGS2MMP2MMP9MMP14 | |
| SCHEMBL3229861 | 0.72 | MMP2 (0.45) | PTGS2MMP2MMP9MMP14POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-7989641-B2 | Methods of synthesizing N-hydroxysuccinimidyl carbonates | XENOPORT, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010017504-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017498-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | CPS1, ASNS, NAAA | PTGS2 1669/4885MMP2 1502/4885MMP9 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.